Guided Therapeutics Inc. has announced the receipt of a $100,000 payment from Shandong Yaohua Medical Instrument Corporation $(SMI.AU)$ via its investment partners. This payment is part of a series of transactions aimed at supporting the commercialization of the LuViva Advanced Cervical Scan in China. The agreement with SMI extends the commercialization efforts of LuViva in China, contingent upon receiving regulatory approval by September this year. Part of the funds will be allocated to supplying SMI and its partner distributors in China with necessary electronic components for LuViva accessories.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。